# Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

> **NCT00767221** · PHASE2 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 20 (estimated)

## Conditions studied

- IGA Nephropathy

## Interventions

- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT00767221
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2009-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00767221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00767221, "Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00767221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*